Impact of expanding indications on surgical and oncological outcome in 1434 consecutive pancreatoduodenectomies

Over the years, high-volume pancreatic centers expanded their indications for pancreatoduodenectomy (PD) but with unknown impact on surgical and oncological outcome. All consecutive PDs performed between 1992–2017 in a single pancreatic center were identified from a prospectively maintained database...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:HPB (Oxford, England) England), 2019-07, Vol.21 (7), p.865-875
Hauptverfasser: van Roessel, Stijn, Mackay, Tara M., Tol, Johanna A.M.G., van Delden, Otto M., van Lienden, Krijn P., Nio, Chung Y., Phoa, Saffire S.K.S., Fockens, Paul, van Hooft, Jeanin E., Verheij, Joanne, Wilmink, Johanna W., van Gulik, Thomas M., Gouma, Dirk J., Busch, Olivier R., Besselink, Marc G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Over the years, high-volume pancreatic centers expanded their indications for pancreatoduodenectomy (PD) but with unknown impact on surgical and oncological outcome. All consecutive PDs performed between 1992–2017 in a single pancreatic center were identified from a prospectively maintained database and analyzed according to three time periods. In total, 1434 patients underwent PD. Over time, more elderly patients underwent PD (P < 0.001) with increased use of vascular resection (10.4 to 16.0%, P < 0.001). In patients with cancer (n = 1049, 74.8%), the proportion pT3/T4 tumors increased from 54.3% to 70.6% over time (P < 0.001). The postoperative pancreatic fistula (16.0%), postpancreatectomy hemorrhage (8.0%) and delayed gastric emptying (31.0%) rate did not reduce over time, whereas median length of stay decreased from 16 to 12 days (P < 0.001). The overall failure-to-rescue rate (6.9%) and in-hospital mortality (2.2%) remained stable (P = 0.89 and P = 0.45). In 523 patients with pancreatic cancer (36.5%), the use of both adjuvant and neoadjuvant chemotherapy increased over time (both p
ISSN:1365-182X
1477-2574
DOI:10.1016/j.hpb.2018.10.020